Moderna (MRNA) Misses Q3 EPS by $1.35, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Moderna (MRNA) Shares Plunge 13% on EPS and Revenue Miss and Slashed Covid-19 Vaccine Sales Guidance
November 4, 2021 8:31 AM EDTShares of Moderna (NASDAQ: MRNA) are down more than 13% in pre-open Thursday after the company delivered disappointing Q3 results and guidance.
Moderna reported Q3 EPS of $7.70, a handy miss compared to the analyst estimate of $9.05. Revenue for the quarter came in at $5 billion versus the consensus estimate of $6.21 billion.
Shares were further hit by the... More
